Dietary fibre, diabetes, and hyperlipidaemia. Progress and prospects.
When diabetes and cardiovascular disease were first classed as possible fibre-deficiency diseases, laboratory and clinical evidence was lacking. Subsequent studies indicated that the gums and viscous types of fibre (e.g., guar and pectin) are more effective than other fibres in slowing carbohydrate absorption and hence in reducing the postprandial rise in blood glucose and serum insulin. This effect has longer term metabolic consequences. In addition, gums and viscous fibres reduce serum cholesterol, possibly by mechanisms other than simply increasing bile-salt loss. If these potential therapeutic effects of fibre are to be exploited, palatable formulations must be developed. The effect of fibre in whole foods should also be determined.
D000924:Anticholesteremic Agents; D002482:Cellulose / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000178:diet therapy*; D004040:Dietary Carbohydrates / Q000378:metabolism; D004043:Dietary Fiber / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000178:diet therapy*; D006938:Hyperlipoproteinemia Type II / Q000178:diet therapy; D000960:Hypolipidemic Agents; D007408:Intestinal Absorption; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors; D013997:Time Factors
D000924:Anticholesteremic Agents; D004040:Dietary Carbohydrates; D004043:Dietary Fiber; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D002482:Cellulose; D002784:Cholesterol